← Evidence map

ArticleCell death & disease2020

Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5

Haoran Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

3 papers cite it

2020
2021
2022
2023
2024
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 33230188